🔎 Trials Near Me

Dachaigh › Liomfoma Neo-Hodgkin › Rhode Island › Providence

Sgrùdaidhean clionaigeach Liomfoma Neo-Hodgkin ann an Providence, RI

Tha 5 sgrùdaidhean airson Liomfoma Neo-Hodgkin a’ lorg phàirtichean aig làraichean ann agus timcheall air Providence (taobh a-staigh mu 30 mìle). Fosglaidh sgrùdadh gus faicinn cò as urrainn pàirt a ghabhail agus mar a chuireas tu fios air an sgioba.

Teacsa sgrùdaidh oifigeil (Beurla)

A’ fastadh airson sgrùdadh an seo? Seall e aig mullach na duilleige seo — $99 airson 30 latha →

A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas

A’ fastadhÌre 1/2
  • Local Institution - 0045, Providence
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 14 Sult 2026 · NCT06090539

Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)

A’ fastadhÌre 1
  • Lifespan Cancer Institute at Rhode Island Hospital, Providence
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 8 Sult 2026 · NCT03666000

Study of SGR-1505 in Mature B-Cell Neoplasms

A’ fastadhÌre 1
  • Rhode Island Hospital, Providence
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 13 Gearr 2026 · NCT05544019

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

A’ fastadhSgrùdadh amharc
  • Massive Bio SYNERGY-AI site, Providence
Gach aois · Gach gnè · Air ùrachadh 28 Dàmh 2025 · NCT03452774

IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers

A’ fastadhÌre 1/2
  • Rhode Island Hospital, Providence
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 3 Ògmh 2025 · NCT06119685

Sgrùdaidhean Liomfoma Neo-Hodgkin ann am bailtean eile

Sgrùdaidhean eile ann an Providence

Bho ClinicalTrials.gov, dàta air a thogail 6 Dàmh 2026. Bidh gach sgrùdadh a’ suidheachadh a chuidi fhèin; bidh an sgioba sgrùdaidh a’ co-dhùnadh cò as urrainn pàirt a ghabhail.